These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 22743097

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 3. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V.
    Cas Lek Cesk; 2006 Feb; 145(5):377-82. PubMed ID: 16755775
    [Abstract] [Full Text] [Related]

  • 8. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy.
    Randolph TR.
    Clin Lab Sci; 2005 Apr 10; 18(1):49-56. PubMed ID: 15747786
    [Abstract] [Full Text] [Related]

  • 14. Imatinib resistance in CML.
    Volpe G, Panuzzo C, Ulisciani S, Cilloni D.
    Cancer Lett; 2009 Feb 08; 274(1):1-9. PubMed ID: 18653275
    [Abstract] [Full Text] [Related]

  • 15. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K, Blasiak J.
    Acta Biochim Pol; 2013 Feb 08; 60(4):503-14. PubMed ID: 24273759
    [Abstract] [Full Text] [Related]

  • 16. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS.
    Leuk Res; 2010 Oct 08; 34(10):1255-68. PubMed ID: 20537386
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM, Melo JV.
    Acta Haematol; 2008 Oct 08; 119(4):212-7. PubMed ID: 18566539
    [Abstract] [Full Text] [Related]

  • 18. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW, Druker BJ.
    Pharmacol Rev; 2003 Sep 08; 55(3):401-23. PubMed ID: 12869662
    [Abstract] [Full Text] [Related]

  • 19. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J.
    Lab Hematol; 2004 Sep 08; 10(3):181-4. PubMed ID: 15529444
    [No Abstract] [Full Text] [Related]

  • 20. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME, Mauro MJ, Druker BJ.
    Annu Rev Med; 2002 Sep 08; 53():369-81. PubMed ID: 11818480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.